Halozyme Expansion of Global Collaboration and License Agreement with argenx

 Four new targets nominated for total of six nominated targets, including FcRn (VYVGART® Hytrulo), for ENHANZE® drug delivery technology

Halozyme to receive total upfront payment of $30 million for exclusive rights to targets

https://www.prnewswire.com/news-releases/halozyme-announces-expansion-of-global-collaboration-and-license-agreement-with-argenx-for-enhanze-302266578.html